The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
Conclusions: This meta-analysis shows that the addition of platinum to chemotherapy regimens in the neoadjuvant setting increases pCR rate in BRCA - mutated as compared to wild-type TNBC patients. However, this trend did not achieve statistical significance.
Trial registration: CRD42018092341.
PMID: 30962858 [PubMed]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T Tags: Hered Cancer Clin Pract Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Conferences | Databases & Libraries | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pathology | Statistics | Study | Women